Jonathan Young Akero Therapeutics, Inc. (AKRO) insider trading activity

Jonathan Young is Chief Operating Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 228,083 shares of AKRO, which is worth approximately $6.69 Million. The most recent transaction as insider was on Dec 16, 2024, when has been sold 24,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 228K

3.47% 3M change

23.2% 12M change

Total Value Held $6.69 Million

Jonathan Young Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2024	BUY Grant, award, or other acquisition	-	24,300 Added 9.63%	228,083 Common Stock
Dec 10 2024	SELL Open market or private sale	$77,067 $30.79 p/Share	2,503 Reduced 1.21%	203,783 Common Stock
Dec 02 2024	SELL Open market or private sale	$321,300 $32.13 p/Share	10,000 Reduced 4.62%	206,286 Common Stock
Nov 01 2024	SELL Open market or private sale	$1,630,519 $32.15 p/Share	50,716 Reduced 18.99%	216,286 Common Stock
Nov 01 2024	BUY Exercise of conversion of derivative security	$858,700 $21.09 p/Share	40,716 Added 13.23%	267,002 Common Stock
Oct 14 2024	SELL Open market or private sale	$1,206,000 $30.15 p/Share	40,000 Reduced 15.02%	226,286 Common Stock
Oct 14 2024	BUY Exercise of conversion of derivative security	$843,600 $21.09 p/Share	40,000 Added 13.06%	266,286 Common Stock
Oct 01 2024	SELL Open market or private sale	$281,800 $28.18 p/Share	10,000 Reduced 4.23%	226,286 Common Stock
Sep 10 2024	SELL Open market or private sale	$14,870 $26.18 p/Share	568 Reduced 0.24%	236,286 Common Stock
Sep 03 2024	SELL Open market or private sale	$135,000 $27.0 p/Share	5,000 Reduced 2.07%	236,854 Common Stock
Aug 01 2024	SELL Open market or private sale	$134,200 $26.84 p/Share	5,000 Reduced 2.03%	241,854 Common Stock
Jul 01 2024	SELL Open market or private sale	$117,000 $23.4 p/Share	5,000 Reduced 1.99%	246,854 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$21,216 $19.94 p/Share	1,064 Added 0.42%	251,854 Common Stock
Jun 11 2024	SELL Open market or private sale	$56,962 $22.64 p/Share	2,516 Reduced 0.99%	250,790 Common Stock
Jun 03 2024	SELL Open market or private sale	$96,450 $19.29 p/Share	5,000 Reduced 1.94%	253,306 Common Stock
May 01 2024	SELL Open market or private sale	$100,750 $20.15 p/Share	5,000 Reduced 1.9%	258,306 Common Stock
Apr 01 2024	SELL Open market or private sale	$10,008 $25.02 p/Share	400 Reduced 0.15%	263,306 Common Stoek
Apr 01 2024	SELL Open market or private sale	$111,917 $24.33 p/Share	4,600 Reduced 1.71%	263,706 Common Stock
Mar 13 2024	SELL Open market or private sale	$18,442 $28.33 p/Share	651 Reduced 0.24%	268,306 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$51,659 $0.62 p/Share	83,321 Added 23.65%	268,957 Common Stock
Dec 27 2023	SELL Open market or private sale	$129,936 $24.0 p/Share	5,414 Reduced 2.84%	185,131 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$34,433 $6.36 p/Share	5,414 Added 2.76%	190,545 Common Stock
Dec 14 2023	SELL Open market or private sale	$11,272 $20.76 p/Share	543 Reduced 0.29%	185,131 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 14.9%	185,674 Common Stock
Nov 17 2023	SELL Open market or private sale	$440,400 $14.68 p/Share	30,000 Reduced 16.38%	153,177 Common Stock

Jonathan Young

Chief Operating Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account